| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2010
|
3.13
|
|
2
|
Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy.
|
Radiology
|
2012
|
2.36
|
|
3
|
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
|
J Clin Oncol
|
2006
|
1.66
|
|
4
|
Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
|
Cancer
|
2006
|
1.42
|
|
5
|
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies.
|
Bioorg Med Chem
|
2010
|
1.40
|
|
6
|
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.
|
Cancer Immunol Immunother
|
2012
|
1.06
|
|
7
|
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
|
Lung Cancer
|
2011
|
1.02
|
|
8
|
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
|
J Thorac Oncol
|
2015
|
0.99
|
|
9
|
Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002).
|
Oncologist
|
2007
|
0.98
|
|
10
|
Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
|
Oncologist
|
2008
|
0.97
|
|
11
|
IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer.
|
Int J Cancer
|
2009
|
0.96
|
|
12
|
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.
|
Clinicoecon Outcomes Res
|
2012
|
0.96
|
|
13
|
Pemetrexed for the treatment of non-small cell lung cancer.
|
Expert Opin Pharmacother
|
2013
|
0.96
|
|
14
|
Gender-related difference in ST-elevation myocardial infarction treated with primary angioplasty: a single-centre 6-year registry.
|
Eur J Prev Cardiol
|
2011
|
0.95
|
|
15
|
Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.
|
J Thorac Oncol
|
2011
|
0.93
|
|
16
|
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
|
Clin Lung Cancer
|
2011
|
0.91
|
|
17
|
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
|
Target Oncol
|
2014
|
0.90
|
|
18
|
Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.
|
J Thorac Oncol
|
2007
|
0.89
|
|
19
|
IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions.
|
PLoS One
|
2009
|
0.89
|
|
20
|
Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression.
|
Int J Cancer
|
2008
|
0.89
|
|
21
|
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
|
Lung Cancer
|
2008
|
0.87
|
|
22
|
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.
|
J Thorac Oncol
|
2015
|
0.86
|
|
23
|
Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.
|
Lung Cancer
|
2010
|
0.85
|
|
24
|
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.
|
Lung Cancer
|
2011
|
0.85
|
|
25
|
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
|
J Thorac Oncol
|
2014
|
0.84
|
|
26
|
Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
|
Crit Rev Oncol Hematol
|
2008
|
0.84
|
|
27
|
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.
|
J Thorac Oncol
|
2014
|
0.84
|
|
28
|
Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients.
|
Mol Cancer
|
2013
|
0.81
|
|
29
|
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.
|
J Cancer Res Clin Oncol
|
2014
|
0.81
|
|
30
|
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
|
Clin Cancer Res
|
2007
|
0.81
|
|
31
|
Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview.
|
Future Oncol
|
2014
|
0.80
|
|
32
|
Outpatient hysteroscopic polypectomy in 237 patients: feasibility of a one-stop "see-and-treat" procedure.
|
J Am Assoc Gynecol Laparosc
|
2004
|
0.80
|
|
33
|
Afatinib for the treatment of advanced non-small-cell lung cancer.
|
Expert Opin Pharmacother
|
2014
|
0.80
|
|
34
|
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer.
|
Expert Opin Biol Ther
|
2012
|
0.80
|
|
35
|
Oral vinorelbine in the treatment of non-small-cell lung cancer.
|
Expert Opin Pharmacother
|
2014
|
0.80
|
|
36
|
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.
|
Oncol Res
|
2005
|
0.79
|
|
37
|
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
|
Eur J Cancer
|
2013
|
0.79
|
|
38
|
Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer.
|
Anticancer Res
|
2008
|
0.79
|
|
39
|
Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective.
|
Eur J Cancer
|
2004
|
0.78
|
|
40
|
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).
|
Eur J Cancer
|
2011
|
0.78
|
|
41
|
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
|
Acta Oncol
|
2006
|
0.78
|
|
42
|
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.
|
Future Oncol
|
2014
|
0.78
|
|
43
|
Lung Cancer Highlights from ASCO 2005.
|
Oncologist
|
2006
|
0.78
|
|
44
|
Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer.
|
Eur J Obstet Gynecol Reprod Biol
|
2006
|
0.77
|
|
45
|
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.
|
Expert Opin Biol Ther
|
2014
|
0.77
|
|
46
|
Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity.
|
Bioorg Med Chem Lett
|
2009
|
0.77
|
|
47
|
CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib.
|
Arch Immunol Ther Exp (Warsz)
|
2015
|
0.77
|
|
48
|
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols.
|
Bioorg Med Chem
|
2011
|
0.76
|
|
49
|
Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
|
Microrna
|
2016
|
0.76
|
|
50
|
Belagenpumatucel-L for the treatment of non-small cell lung cancer.
|
Expert Opin Biol Ther
|
2015
|
0.76
|
|
51
|
Saline infusion sonography and office hysteroscopy to assess endometrial morbidity associated with tamoxifen intake.
|
Gynecol Oncol
|
2002
|
0.76
|
|
52
|
Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?
|
Curr Med Res Opin
|
2014
|
0.75
|
|
53
|
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma.
|
J Thorac Oncol
|
2015
|
0.75
|
|
54
|
Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
55
|
Mobile emergency, an emergency support system for hospitals in mobile devices: pilot study.
|
JMIR Res Protoc
|
2013
|
0.75
|
|
56
|
To treat or not to treat advanced non-small-cell lung cancer patients with impaired performance status?
|
J Clin Oncol
|
2005
|
0.75
|
|
57
|
Dynamic behaviour of lactate values during mild hypothermia in patients with cardiac arrest.
|
Eur Heart J Acute Cardiovasc Care
|
2013
|
0.75
|
|
58
|
Hysteroscopic assessment of menopausal breast-cancer patients taking tamoxifen; there is a bias from the mode of endometrial sampling in estimating endometrial morbidity?
|
Breast Cancer Res Treat
|
2002
|
0.75
|
|
59
|
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy.
|
Anticancer Agents Med Chem
|
2016
|
0.75
|
|
60
|
Hematopoietic growth factors in lung cancer.
|
Curr Opin Oncol
|
2016
|
0.75
|
|
61
|
Efficacy of motesanib diphosphate in non-small-cell lung cancer.
|
Expert Opin Pharmacother
|
2014
|
0.75
|